Description
+ Include: videos + file sub vtt + pdf, size: GB
+ Target Audience: oncologists, neurosurgeons, radiation oncologists
+ Sample video: contact me for sample video
+ Information:
This didactic and case-based course will provide a comprehensive update on the latest advances in the treatment and research of brain metastases. Aimed at clinicians and translational scientists, this course will provide an update on CNS-specific outcomes from both molecular and traditional cancer histology viewpoints.
Recent evidence for brain metastasis activity will be highlighted for key medical targets (e.g. Her2, EGFR, KRAS, CDK, BRAF, and ALK), and leading experts will review brain metastasis prognosis across the cancers commonly resulting in this (lung, breast, and melanoma).
A dedicated session on recent developments in local therapy will review the role of laser interstitial thermal therapy, brachytherapy and external beam radiation techniques. In recognition of the many complex treatment interactions imposed by multimodality treatment often necessary, a ‘Key Controversies’ session will speak to major areas of clinical difficulty, for example, how to distinguish on recurrent disease from radiation necrosis on imaging studies, when to change therapy with CNS-only progressive disease, which leptomeningeal metastasis interventions are currently worthwhile, and special considerations regarding steroid use and radiation therapy for patients requiring immunotherapy.
Key scientists will discuss promising translational and clinical trial approaches including targeting metastasis-initiating cells and window-of-opportunity studies. Given the special challenge of early detection, a dedicated session will cover state-of-the art molecular imaging techniques, the evidence for/against imaging surveillance in standard-risk cancers, and the current state of liquid biopsy.
A roundtable discussion with participants from several centers will share their experiences and best practices with multidisciplinary team care and discuss areas for improvement. Finally, a multidisciplinary tumor board will review multifaceted cases, highlighting the interplay of various treatment options.
There will be ample opportunity for networking with speakers and other participants in this virtual meeting.
- Describe the current multimodal landscape of brain metastasis treatment
- Identify key clinical controversies in brain metastasis management
- Discuss barriers to improved treatments and potential research strategies (e.g. limited CNS activity of systemic anti-cancer treatments, side effects of local treatments, limited survival, and unclear endpoints)
The Memorial Sloan Kettering Cancer Center Advanced Therapeutics for Brain Metastasis 2026 is best for oncologists, neurosurgeons, radiation oncologists, and researchers who want to deepen their expertise in the management of brain metastases. It emphasizes cutting‑edge therapeutics, multidisciplinary care, and translational science to improve survival and quality of life for patients with metastatic brain disease.
👩⚕️ Target Audience
- Medical oncologists managing systemic therapies for patients with brain metastases.
- Radiation oncologists & neurosurgeons specializing in stereotactic radiosurgery, whole‑brain radiation, and surgical resection.
- Neuro‑oncologists focusing on CNS complications of systemic cancer.
- Researchers & scientists studying tumor biology, immunotherapy, and targeted agents for brain metastases.
- Pharmacologists & industry professionals developing novel therapeutics for CNS disease.
- Residents & fellows training in oncology, neurosurgery, or radiation oncology.
- Multidisciplinary care teams (nurses, physician associates, rehabilitation specialists) supporting patient outcomes.
📚 What Participants Gain
- Therapeutic updates: immunotherapy, targeted therapy, and novel systemic agents crossing the blood‑brain barrier.
- Radiation & surgical advances: stereotactic radiosurgery, minimally invasive neurosurgery, and combined modality approaches.
- Clinical trial insights: ongoing and emerging studies in brain metastasis treatment.
- Multidisciplinary strategies: integrating oncology, neurosurgery, radiation, and supportive care.
- Case‑based learning: real patient scenarios to sharpen decision‑making.
- Scientific frontiers: translational research bridging lab discoveries with clinical practice.
+ Topics:
Wednesday, September 9, 2026
| Time | Topic | Speaker(s) |
| 8:10 – 8:30 am | Brain Metastases: From Population Health to Precision Medicine | Matthias Preusser, MD |
| 8:30 – 8:35 am | Patient Perspectives on Living with Brain Metastases | Julia Maues, MA |
| 8:35 – 8:40 am | Q&A and Panel Discussion | |
| 8:40 – 8:55 am | Breast Cancer: Navigating the ADC Era — Efficacy, Toxicity, and Sequencing | Carey K. Anders, MD |
| 8:55 – 9:10 am | Melanoma Brain Metastases: Systemic Therapy Update | Hussein Tawbi, MD, PhD |
| 9:10 – 9:25 am | Thoracic Oncology Update | Gregory Riely, MD |
| 9:25 – 9:35 am | Q&A and Panel Discussion | Priya Kumthekar, MD (Moderator) |
| 9:45 – 10:00 am | Modern SRS: Fractionation Strategies and Combination with Systemic Therapy | Michelle Kim, MD |
| 10:00 – 10:15 am | Cs-131 Brachytherapy for Recurrent Brain Metastases | Nelson Moss, MD; Brandon Imber, MD |
| 10:15 – 10:30 am | Laser Interstitial Thermal Therapy: Expanding Indications and Long-term Outcomes | Veronica Chiang, MD |
| 10:30 – 10:45 am | Surgical Decision-Making in the Age of Effective Systemic Therapy | Gelareh Zadeh, MD, PhD |
| 10:45 – 10:55 am | Q&A and Panel Discussion | |
| 11:00 – 11:20 am | Biology, Imaging, and Pathophysiology of Leptomeningeal Disease | Michael Weller, MD |
| 11:20 – 11:40 am | CSF Liquid Biopsy and Biomarkers for Leptomeningeal Disease | Chetan B Bettegowda, MD, PhD |
| 11:40 – 11:50 am | Q&A and Panel Discussion | Jessica Wilcox, MD (Moderator) |
| 12:00 – 12:20 pm | Upfront Brain-Directed Therapy vs Systemic-First Approaches |
Brain-Directed: Luke R. G. Pike, MD, DPhil
Systemic-First: Manmeet Singh Ahluwalia, MD |
| 12:20 – 12:35 pm | ADC-Associated CNS Toxicity: Mechanism, Recognition, and Management | Yao Yu, MD |
| 12:35 – 12:50 pm | Where Radiation Fits in the Era of Potent Systemic Therapy | Ayal Aizer, MD |
| 12:50 – 1:00 pm | Q&A and Panel Discussion | |
| 1:50 – 2:05 pm | Breast Cancer Controversies in the ADC Era | Paolo Tarantino, MD |
| 2:05 – 2:20 pm | Immunotherapy-Related CNS Toxicity: Real-World Data and Management | Isabella C Glitza Oliva, MD, PhD, MS |
| 2:20 – 2:35 pm | Advanced Imaging: Amino Acid PET, AI, and Radiomics for Distinguishing Progression from Treatment Effect | Norbert Galldiks, MD |
| 2:35 – 2:45 pm | Q&A and Panel Discussion | Joshua A Budhu, MD, MPH (Moderator) |
| 2:55 – 3:15 pm | Microenvironment and Metastatic Niche: New Therapeutic Targets | Josh Neman, PhD |
| 3:15 – 3:30 pm | Brain Metastasis Microenvironment | Nathalie Agar, PhD |
| 3:30 – 3:50 pm | FDA Perspectives on Brain Metastasis Clinical Trials: Endpoints, Design, and Regulatory Considerations | Tatiana Prowell, MD |
| 3:50 – 4:05 pm | Q&A and Panel Discussion | Minesh Mehta, MD (Moderator) |
| 4:05 – 5:00 pm | Multidisciplinary Tumor Board | Andrew D Seidman, MD; Brandon Imber, MD; Gregory Riely, MD; Robert Young, MD |
Reviews
There are no reviews yet.